By

Andrea Dautant

Tech Tuesday – Charlie Li

In this week's Tech Tuesday for WCJB TV20, UF Innovate's Melanie Morón interviews Charlie Li, professor in the UF|IFAS Department of Agricultural and Biological Engineering about improving agricultural efficiency and increasing output for farmers. Through advanced AI and robotics technology, Li and his team are solving some of the most challenging problems facing our food systems.

Hernando County Government Streamlines Permitting Process With AutoReview.AI

The Hernando County Board of County Commissioners recently approved the onboarding of AutoReview.AI to streamline the permit approval process and review development plans for compliance purposes. AutoReview.AI, a UF startup and UF Accelerate resident client, specializes in elevating efficiency by reviewing land and permits in seconds using their artificial intelligence technology. This ensures accuracy when tracking compliance and allows planners to focus on the more specific and nuanced parts of community development.

Is the Calabaza the Next Great Gourd for Growers in the Southeastern U.S.? UF/IFAS Is One Step Closer to a Choice Cultivar

Researchers at the University of Florida's Institute of Food and Agricultural Sciences are establishing the Calabaza as a choice cultivar in the Southeast. Geoffrey Meru, a UF/IFAS vegetable geneticist and his team at the UF/IFAS Tropical Research and Education Center in Homestead have laid the groundwork to make Calabaza a choice cultivar for growers in the southeast. They hope to release the powerful potential of the calabaza that packs a punch for its nutritional content, adaptability and sustainability.

Tech Tuesday – etectRx

Tech Tuesday with Eric Buffkin, CEO of etectRx, as he outlines the company's newest partnership with the Village in Gainesville to improve incontinence monitoring, elevate care for seniors, and alleviate pressure on staff.

Atsena Therapeutics Announces Positive 12-Month Safety and Efficacy Data From Ongoing Phase I/II Clinical Trial To Treat Leber Congenital Amaurosis

Atsena Therapeutics announced positive results in their 12-month safety and efficacy data from the ongoing Phase I/II trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 has conferred clinically meaningful improvements in vision at the highest dose with no serious treatment-emergent adverse events.